VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$368M
(+188%)
Cap. Flow
+$240M
Cap. Flow
% of AUM
65.16%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
BridgeBio Pharma
BBIO
$9.91B
| $449K | 0.12% |
+12,978
| New | +$449K |
|
202
Axsome Therapeutics
AXSM
$6.09B
| $444K | 0.12% |
+3,806
| New | +$444K |
|
203
Gilead Sciences
GILD
$140B
| $439K | 0.12% |
+3,920
| New | +$439K |
|
204
Ascendis Pharma
ASND
$12.1B
| $428K | 0.12% |
+2,747
| New | +$428K |
|
205
Morgan Stanley Direct Lending Fund
MSDL
$1.56B
| $422K | 0.11% |
+21,135
| New | +$422K |
|
|
SWTX
206
DELISTED
SpringWorks Therapeutics
SWTX
| $409K | 0.11% |
+9,279
| New | +$409K |
|
207
Amgen
AMGN
$153B
| $408K | 0.11% |
+1,309
| New | +$408K |
|
208
Alnylam Pharmaceuticals
ALNY
$58.6B
| $396K | 0.11% |
+1,467
| New | +$396K |
|
209
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $396K | 0.11% |
+17,828
| New | +$396K |
|
210
Madrigal Pharmaceuticals
MDGL
$9.7B
| $394K | 0.11% |
+1,188
| New | +$394K |
|
211
PTC Therapeutics
PTCT
$4.41B
| $386K | 0.11% |
+7,583
| New | +$386K |
|
212
BioMarin Pharmaceuticals
BMRN
$11.3B
| $383K | 0.1% |
+5,416
| New | +$383K |
|
213
Mirum Pharmaceuticals
MIRM
$3.75B
| $383K | 0.1% |
+8,492
| New | +$383K |
|
214
ADMA Biologics
ADMA
$4.03B
| $382K | 0.1% |
19,230
+4,250
| +28% | +$84.3K |
|
215
Insmed
INSM
$30.3B
| $380K | 0.1% |
+4,986
| New | +$380K |
|
216
Exelixis
EXEL
$9.95B
| $377K | 0.1% |
10,209
-2,791
| -21% | -$103K |
|
217
Vertex Pharmaceuticals
VRTX
$102B
| $375K | 0.1% |
+773
| New | +$375K |
|
218
Harmony Biosciences
HRMY
$2.16B
| $374K | 0.1% |
11,268
+7,668
| +213% | +$255K |
|
219
Krystal Biotech
KRYS
$4.35B
| $373K | 0.1% |
+2,068
| New | +$373K |
|
220
Tarsus Pharmaceuticals
TARS
$2.44B
| $361K | 0.1% |
+7,025
| New | +$361K |
|
221
Travere Therapeutics
TVTX
$1.75B
| $359K | 0.1% |
+20,046
| New | +$359K |
|
222
Dynavax Technologies
DVAX
$1.19B
| $358K | 0.1% |
+27,636
| New | +$358K |
|
223
ImmunityBio
IBRX
$2.24B
| $355K | 0.1% |
+118,100
| New | +$355K |
|
224
BioCryst Pharmaceuticals
BCRX
$1.74B
| $354K | 0.1% |
+47,239
| New | +$354K |
|
225
Immunocore
IMCR
$1.78B
| $352K | 0.1% |
+11,847
| New | +$352K |
|